CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer

CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer

Herein, Liu and colleagues show that CD4+ T cells in cytokine-induced killer (CIK) cells are required to enhance the clinical efficacy of CIK therapy. In addition, CD4+ T cells help via IL-17A production is critical to restoring the function of CD8+/CD3+CD56+ T cells and reversing the exhaustion of...

Full description

Bibliographic Details
Main Authors: Shaochuan Liu, Yuan Meng, Liang Liu, Yingge Lv, Wenwen Yu, Ting Liu, Limei Wang, Di Mu, Qiuru Zhou, Min Liu, Yulin Ren, Dong Zhang, Baihui Li, Qian Sun, Xiubao Ren
Format: Article
Language:English
Published: Nature Publishing Group 2022-05-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-022-04882-x

Internet

https://doi.org/10.1038/s41419-022-04882-x

Similar Items